Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: weatherproof who wrote (49396)	1/20/2019 2:50:34 PM
From: bobbseytwins2001	8 Recommendations Recommended By bnutman dorightbythem drtom1234 idahoranch1 immuapproval and 3 more members Respond to of 63283

While all this blame speculation is interesting, we cannot help thinking of all the triple negative breast cancer patients, who have been affected by this CRL decision. According to the numbers about 10,000 women in the U.S. are diagnosed each year. Most succumb to this deadly disease within several months and it defeats almost all later on. If our numbers are correct on average around 80 have passed away just since the CRL announcement on Thursday. Of course 132 would not have saved all of them, but it might eventually help. In addition on average another 27 or so will die today, 27 more tomorrow and so on. The FDA says 132 is safe and effective, so how can anyone justify letting this drag on without a fight? Certainly many people have been shocked by this news and will be trying to ascertain what manufacturing "process" issue could be so unfixable to generate the CRL, especially when there is a 1 1/2 year supply of 132 on hand. Women in general seem to be more assertive every day. Concerned women's organizations as well as all of us should be talking to our representatives to implore them to make this right if possible. To us this whole episode in unconscionable and must be remedied immediately, not months or years from now.